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Abstract
Background: The mechanism by which HIV infection leads to a selective depletion of CD4 cells leading to
immunodeficiency remains highly debated. Whether the loss of CD4 cells is a direct consequence of virus infection
or bystander apoptosis of uninfected cells is also uncertain.
Results: We have addressed this issue in the humanized mouse model of HIV infection using a HIV variant with a
point mutation in the gp41 region of the Env glycoprotein that alters its fusogenic activity. We demonstrate here
that a single amino acid change (V38E) altering the cell-to-cell fusion activity of the Env minimizes CD4 loss in
humanized mice without altering viral replication. This differential pathogenesis was associated with a lack of
bystander apoptosis induction by V38E virus even in the presence of similar levels of infected cells. Interestingly,
immune activation was observed with both WT and V38E infection suggesting that the two phenomena are likely
not interdependent in the mouse model.
Conclusions: We conclude that Env fusion activity is one of the determinants of HIV pathogenesis and it may be
possible to attenuate HIV by targeting gp41.
Introduction
HIV infection in humans leads to a selective depletion
of CD4+ T cells that culminates in immunodeficiency
or AIDS. While it is clear that the loss of CD4+ T cells
is initiated by HIV infection, the mechanism behind this
phenomenon remains highly debated. CD4 T cell loss
can occur due to multiple mechanisms: direct killing of
infected cells [1], indirect killing of uninfected cells [2],
a defect in the capacity for lymphocyte proliferation or
turnover or both [3], and/or an overzealous chronic
immune response and immune activation [4]. The con-
tribution of these processes to CD4 depletion in vivo
remains incompletely understood. However, the number
of infected cells detectable in HIV-infected individuals
is much lower than can account for the profound
loss of CD4+ T cells seen with disease progression.
Furthermore, SIV infection of the natural hosts in the
wild show limited CD4 decline despite active viral repli-
cation [5,6], suggesting that virus infection per se does
not lead to CD4 T cell destruction. Because of these
reasons, it has been proposed that apoptosis of unin-
fected bystander cells may contribute to the depletion of
CD4+ T cells [7-9]. In fact, the majority of T cells
undergoing apoptosis in peripheral blood and lymph
nodes of HIV patients are uninfected [10]. Moreover,
massive apoptosis was predominantly observed in unin-
fected CD4+ T cells present in lymph nodes, thymus or
spleen in animal models, such as rhesus macaques
infected by SIV or highly pathogenic SIV/HIV chimeric
viruses [11,12].
Several HIV-1 proteins, such as HIV envelope glyco-
protein Env [13-15], Nef [16,17], Tat [18,19] and Vpr
[20,21] can induce T cell apoptosis. However, which of
these factors are important in vivo is not clear, although
cumulative data suggest a major role of Env in cell
death of uninfected lymphocytes [22]. Under experimen-
tal conditions, Env, either in a soluble [8] or membrane-
bound form [23,24], can induce the death of uninfected
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brane fusing activity of the Env glycoprotein has been
shown to be critical for CD4 loss [25,26]. However,
which mechanism is pertinent for the destruction of
CD4 T cells in vivo has not been examined under con-
trolled conditions. We have previously characterized a
HIV variant with a single amino acid mutation in the
gp41 (V38E) that exhibited deficiency in cell-to-cell
fusion activity and apoptosis induction in vitro as well
as increased Enfuvirtide resistance [27]. Using this virus
as a model system, in this study, we have compared the
pathogenicity of WT and V38E mutant in the huma-
nized mice and find that while both viruses replicate to
similar levels and induce immune activation, V38E
mutant is compromised in its ability to induce a pro-
gressive CD4 T cell loss consequent to its failure to
induce bystander apoptosis.
Methods
Virus Stock and plasmids
Virus stocks were prepared with molecular clones of the
WT virus or V38E mutant as described previously [28].
Briefly, virus stocks were prepared by 293T transfection
using infectious molecular clones and Ex Gen 500 trans-
fection reagent. Virus supernatant was collected 48h post
transfection, cleared of cellular components by centrifuga-
tion, aliquoted and stored at -70°C. WT virus contains the
Lai ENV in NL4-3 backbone and the mutant V38E was
generated by site directed mutagenesis and have been
described previously [27,28]. Virus preparations were
quantified using Reverse Transcriptase (RT) activity assay
as well as titration in TZMbl indicator cell line (NIH
AIDS research and reference reagent program). Enfuvir-
tide (NIH AIDS research and reference reagent program)
resistance was determined in TZMbl cell infection.
In vitro infection and Apoptosis detection
SupT1 cells (NIH AIDS research and reference reagent
program) [29] were infected with equal RT activity units
of viruses and cultured for indicated times. The cultures
were split 1:3 every other day and culture supernatants
were harvested for determination of RT activity. Cells
were collected at day 3 or day 5 post infection, fixed
and permeabilized and stained with anti-p24 RD-1 anti-
body clone KC57 (Beckman Coulter) for detection of
virus infection and with activated caspase indicator,
ZVAD-FITC (Promega) for apoptosis. Flow cytometry
was performed on the samples on a FACS CANTO-II
flow cytometer. Data was analyzed using FACS DIVA
software with at least 20,000 events acquired for each
sample. At day 3 or 5 postinfection, cells were also
assayed for viability using the Cell Titer Glo (Promega)
viability assay. Supernatants from the cultures were
assayed for virus replication using RT assay.
Virus Replication Assay
Peripheral blood was collected from healthy volunteers
at Texas Tech University Health Sciences Center
(TTUHSC) under protocol approved by the TTUHSC
Institutional Review board. PBMCs were separated
from whole blood by Ficoll density centrifugation.
CD4+ T cells were isolated using negative selection
with immunomagnetic beads (Invitrogen). Naïve CD4+
T cells were activated using 5 μg/ml PHA and 25U/ml
IL-2 (NIH AIDS Reference and Reagent Program) for
3 days prior to infection. Equal RT units of virus were
used to infect the CD4+ PBMCs and cultured for 18
days. Supernatants collected at different time points
were assayed for RT activity to determine virus
replication.
Generation of Humanized mice
Humanized BLT mice used in the study were generated
as described [30]. Briefly NOD SCID IL2Rg-/- mice
were obtained from Jackson Laboratory (Bar Harbor,
ME) and housed at the Texas Tech animal facility as
per institutional guidelines. Fetal tissue was obtained
from Advanced Bioscience Resources (Alameda, CA).
Mice were irradiated with 3gy total body irradiation
prior to surgical transplantation of fetal thymus and
liver tissue (1-3 mm) under the kidney capsule. CD34+
stem cells were isolated from the fetal liver the same
day using positive selection with anti-CD34 coated
microbeads (Miltenyi Biotec, Auburn, CA). 5X10
5
CD34
+ cells were injected in the mice IV following
tissue implantation. Human cell expansion and repopu-
lation was determined 10-12 weeks post implantation by
multicolor flow cytometric analysis by staining of
PBMCs with CD45, CD4 and CD8 antibodies (Beckman
Coulter). All use of human tissues and animals was as
per institutional guidelines and approved by the Institu-
tional Review Board at TTUHSC.
Infection of Humanized mice
BLT mice at 12-14 weeks post reconstitution were
infected with 50,000 TCID50 of virus stocks intraperito-
neally. Total of four mice per group were infected with
either WT or V38E virus. However one mouse in the
V38E and WT group was lost at 2 and 4 weeks respec-
tively during bleeding. Data from all 4 mice is included
where available. Peripheral blood was collected from the
mice by retro orbital bleeding every 2 weeks for a total
of 8 weeks. PBMCs collected at each time point were
stained for CD45, CD4, CD8, HLADR, and PD-1. At the
8 weeks end point mice were sacrificed and the spleens
were collected and divided in half. One half was fixed in
neutral buffered formalin for immunohistopathology.
The other half was used for isolation of splenocytes and
staining as above. In addition to HLADR and PD-1,
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8 week end point.
Immunohistopathology
Formalin fixed tissue was paraffin embedded and
sectioned. Antigen retrieval was performed using micro-
wave. Sections were stained with FITC conjugated anti-
caspase 3 antibody (Beckman Coulter) and RD-1
conjugated anti-p24 antibody KC57 clone (Beckman
Coulter) at 1:200 dilution overnight. After extensive
washing the slides were stained with DAPI (Antifade)
(Invitrogen) and observed under fluorescence micro-
scopy (Nikon Ti Eclipse microscope). Fluorescent
images were collected using NIS image acquisition and
analysis software (Nikon). Automated quantitation was
performed with NIS software to determine total p24,
caspase or DAPI stained cells.
Recovery of virus from PBMCs
DNA was extracted from PBMCs using Qiagen DNA
isolation kit. Nested PCR used for amplification of gp41
region has been described by others Aquaro et al [31].
Virus was recovered from PBMCs of infected mice at 8
weeks post infection by coculturing of PHA (5 μg/ml)
and IL-2 (25U/ml)-activated PBMCs (5X10
5 cells) with
10
6 SupT1 cells. RT activity was determined at different
time points and supernatants collected for virus sequen-
cing. Formation of syncytia was recorded on day 10
when virus replication was at the peak.
Results
V38E virus fails to induce bystander apoptosis in SupT1
cells even in the presence of active viral replication
To test the hypothesis that HIV Env mediated bystander
apoptosis and CD4 decline are dependent on gp41 func-
tion, we used V38E mutant in comparison to WT virus.
V38E Env glycoprotein is restricted in bystander apopto-
sis induction in coculture experiments where Env
expressing cells (Hela-Env) are cocultured with CD4
and CXCR4 expressing target cells (SupT1) [27].
Whether the same would be true in cells infected with
HIV remains uncertain. To address this issue, we
infected SupT1 cells with either WT or V38E virus and
subsequently determined bystander cell death during
active virus replication. Cells were stained with p24
(gag) antibody to detect infection and with Z-VAD
FITC to detect activated caspase as a marker for apopto-
sis. As shown in Figure 1A, on days 3 and 5 post infec-
tion, numerous p24+ cells were seen in both WT and
V38E virus infected cells, confirming infection. However,
apoptotic cells were largely restricted to the WT virus
infection. Interestingly, a majority of active caspase+
cells in WT virus infected culture were p24 negative,
validating that these were in fact bystander cells
consistent with data by Holm et al [9]. The fact that
under similar experimental conditions V38E mutant
failed to induce apoptosis in bystander cells suggests
that bystander cell apoptosis induced by HIV infection
is dependent on gp41 function. Quantitation of p24
positivity and apoptosis shown in Figure 1B and 1C
respectively confirms that while p24+ cells are present
in both viral infection, apoptosis is largely restricted to
WT virus infection. Although the total percentage of
p24+ cells in Figure 1b appears to be higher in WT cul-
tures, this is largely because of loss of cells due to both
syncytia formation and apoptosis early on in WT cul-
tures. In fact, viral titers in the culture supernatants,
determined by RT activity, was higher for V38E virus
than WT on day 7 (Figure 1D). The loss of cells due to
syncytia formation and/or apoptosis was also revealed in
total cell viability assay by measuring cell-associated
ATP (Figure 1E). Interestingly, the loss of viability in
WT infected cells was quite significant at both day 3
and day 5, confirming the results seen with the apopto-
sis marker. Taken together, these findings suggest that
V38E mutant is replication competent, yet deficient in
inducing bystander apoptosis due to the limited fusion
activity of the gp41 glycoprotein. The Enfuvirtide resis-
tance of the V38E mutant was also confirmed in TZM
cell line assay (Figure 1F). We next asked whether the
replication potential of V38E virus is restricted to cell
lines like SupT1 where the receptor and coreceptors are
relatively high or the same phenomenon is also true for
PBMCs. Infection of activated CD4+ PBMCs with WT
or V38E virus showed robust replication by both viruses.
Here again we saw that V38E, in fact, replicates much
better than the WT virus (Figure 1G), consistent with
our hypothesis that gp41 mutants with reduced cell-to-
cell fusion activity are unable to induce bystander apop-
tosis and hence have more targets available for infection.
The replication potential of V38E virus in PBMCs also
s u g g e s t e dt h a ti tw o u l db ep o s s i b l et oc o n d u c to u rs t u -
dies in humanized mice to test the pathogenesis of the
mutant.
V38E mutant is attenuated in inducing CD4 decline in
humanized mice
Various humanized mouse models have been shown to
be highly representative for HIV pathogenesis studies
[32-34]. Among these models, the BLT mouse model
for HIV infection is generated by transplanting human
fetal thymus and liver tissue under the kidney capsule of
NOD/SCID/IL2Rg-/- mice followed by iv injection of
fetal liver-derived CD34+ hematopoietic stem cells [30].
This model has recently been shown to reflect HIV
pathology strikingly similar to humans including high
levels of viremia, CD4 decline as well as immune activa-
tion associated with virus infection [35,36]. We infected
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Figure 1 Bystander apoptosis is induced by WT, but not V38E mutant virus infection in vitro. (A) SupT1 cells infected with WT or V38E
virus were stained with anti-p24 Ab to detect virus infection and ZVAD-FITC to detect apoptosis induction on days 3 and 5 post infection.
Cumulative data on virus infection (B) and apoptosis (C) on days 3 and 5 postinfection is shown. (D) Virus replication in the cultures was
determined by measuring RT activity in culture supernatants. (E) Cell viability in the cultures was determined by measuring ATP levels in cells
using cell titer Glo assay. (F) TZMbl cells were infected with either WT or V38E virus in the presence of indicated concentration of Enfuvirtide.
Infection was determined 24h later as luciferase activity and normalized to media control. (G) CD4+ T cells were isolated from whole blood
PBMCs and stimulated with PHA (5 μg/ml) and IL-2 (25U/ml) for 3 days. Subsequently the cells were infected with equal RT units of either WT
or V38E virus or mock infected and followed for virus replication by determining the RT activity in culture supernatants. All error bars show
mean ± SD of triplicate observations.
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Page 4 of 13the BLT mice with 50,000 TCID50 of either WT or
V38E virus and followed them for virus replication and
CD4 decline, by measurement of CD4 T cell percentage
from before infection to 8 weeks post infection. While
peak viremia occurred in both WT and V38E infected
mice by 6 weeks, the decline in CD4 counts was signifi-
cantly higher in WT infected mice compared to V38E
virus infected mice (Figure 2A). This difference was also
maintained at the 8 weeks end point of our study when
we looked at the CD4 levels in the spleen (Figure 2B).
In a repeat of the study in a larger set of mice consisting
of 6 mice per group the results were identical (Addi-
tional file 1, Figure S1), confirming the differential loss
of CD4 cells in WT versus V38E infections. However,
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replication. Hu-HSC mice were infected with 50,000 TCID50 of viruses and bled every 2 weeks for a total of 8 weeks and then sacrificed. (A)
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levels in both the groups was almost identical (Figure
2C), suggesting that the decline was not due to virus
infection per se, but probably due to differences in the
induction of bystander apoptosis. This data also suggests
that in the BLT mouse model the decline in CD4 cells is
not related directly to virus replication but more so to
the phenotype of the Env glycoprotein.
WT virus infection is characterized by extensive bystander
apoptosis in the spleen
To directly test whether the differential CD4 decline is
due to differences in the induction of bystander apopto-
sis, we stained spleen sections of infected mice with
anti-p24 antibody for detection of infected cells and
anti-active caspase-3 antibody as a marker for apoptosis.
In the WT virus infected mice, numerous apoptotic
cells were detected alongside p24+ cells (Figure 3A). In
striking contrast, apoptotic cells were almost undetect-
able in the spleens of V38E virus infected mice (Figure
3B), even in the presence of similar levels of p24+ cells
as in the WT group. Moreover, the apoptotic cells in
WT virus infected mice were largely uninfected (p24
negative) bystander cells that were in close proximity to
the infected cells (Figure 3A), consistent with the find-
ing in lymph node sections from HIV infected indivi-
duals that apoptosis is largely restricted to bystander
cells in close proximity to infected cells [10]. Quantita-
tive analysis of at least 6 images from 2 different slides
from each mouse confirmed that while both WT and
V38E virus showed similar levels of p24 staining consis-
tent with our cell line data and plasma viremia, there
was little to no apoptosis in V38E infected mice (Figure
3C), suggesting that a single point mutation in gp41
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Figure 3 V38E mutant fails to induce bystander apoptosis in vivo. Spleens isolated 8 weeks post infection were fixed in formalin and
sectioned. Paraffin embedded sections were stained with anti-p24 RD-1 antibody (red), active caspase 3 antibody (green) and the nuclear stain,
DAPI (blue). Individual channels and merge images for WT (A) and V38E mutant (B) infected mice spleens are shown. Enlarged images (right
most) from A and B show the presence of apoptotic cells in close proximity to infected cells in WT, but not V38E infected mice. (C) Automated
fluorescence quantitation of total (DAPI), apoptotic (Caspase) and infected cells (p24) from at least 6 images from 2 different slides from each
mice was performed using NIS elements image analysis software (Nikon). Each symbol represents an individual mouse and the horizontal lines
represent the mean.
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Page 6 of 13(V38E) is enough to abrogate bystander apoptosis but
not virus replication.
V38E mutant replicates in humanized mice without
reverting to WT
Our hypothesis is that the point mutation in gp41
restricts the Env fusogenic activity and consequently
bystander apoptosis and CD4 decline in vivo. While the
preceding data supports the hypothesis, we wanted to
make sure that the V38E mutant had not reverted to
WT in the 8-week infection period. To address this
issue, we recovered virus from infected mice PBMCs
after coculture with SupT1 cells (Figure 4A). At the
same time we also isolated DNA from PBMCs and
amplified the gp41 region for sequencing [31]. The
recovered virus from each of the V38E virus infected
mice showed lack of syncytia formation in contrast to
WT virus that induced numerous syncytia (Figure 4B).
Sequence analysis of proviral DNA also confirmed that
the V38E virus had not reverted to WT virus after 8
weeks of infection and that there were no other changes
in the gp41 region (Figure 4C). Hence the V38E virus
was both genotypically and more importantly phenotypi-
cally identical to the input virus. This suggests that the
differential pathogenesis of the viruses can be attributed
to the point mutation in gp41 and the associated lack of
cell-to-cell fusion activity. Taken together, our results
suggest that bystander apoptosis in the humanized
mouse model significantly contributes to the CD4
decline in HIV infection in vivo and that it is most likely
dependent on gp41-mediated fusion activity.
Both WT and V38E viruses mediate immune activation in
CD8 cells
Immune activation is a hallmark of HIV infection [4]
and correlates with CD4 decline in HIV infection [37].
Recently this phenomenon has also been demonstrated
in the humanized mouse model [35,36], prompting us
to ask whether immune activation correlated with CD4
decline in our study. We looked at HLADR and PD-1,
two well established markers associated with HIV dis-
ease progression [37,38], on both CD4 and CD8 cells.
Interestingly we found that upregulation of HLA-DR
(Figure 5A and 5B) and PD-1 (Figure 5C and 5D) was
largely restricted to CD8 T cells in both peripheral
blood and spleen (Figure 5E) over the 8-week period of
our study. The immune activation being restricted to
CD8 cells in this model is consistent with other recent
studies. More importantly, we found that HLA-DR and
PD-1 upregulation was seen in both the WT and V38E
infected groups. This suggests that the two viruses were
not significantly different in mediating immune activa-
tion. The limited CD4 decline in V38E infected group
also suggests that immune activation and CD4 decline
are probably not interdependent in the humanized
mouse model.
Immune activation correlates with CD4 decline in WT
virus but not V38E mutant
While the upregulation of immune activation markers is
a hallmark of HIV disease we wanted to know whether
CD4 decline correlated with im m u n ea c t i v a t i o ni nt h i s
model. We conducted a correlation analysis using
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Page 7 of 13Pearson’s correlation coefficient where we compared
CD4 decline to immune activation in CD8 cells. Corre-
lation of CD4 decline and HLADR (Figure 6A and 6B)
or PD-1 (Figure 6C and 6D) expression on CD8 cells
was determined for both the WT virus as well as V38E
mutant. Interestingly we found that the decline of CD4
cells correlates with HLADR (P = 0.044) (Figure 6A)
and PD-1 (P = 0.042) (Figure 6C) expression on CD8
cells in the WT group similar to HIV infected patients
[37,38] as well as humanized mice [36,39]. However this
A
V38E WT
H
L
A
Ͳ
D
R
24 5 3 27
CD8 CD4 B
V38E WT
H
L
A
Ͳ
D
R
SSC
H
H
SSC
20
25
30
A
D
R
 
+
WT 1
WT 2 20
25
30
A
D
R
+
V38E 1
V38E 2
V38E3
20
25
30
A
D
R
+
WT 1
WT2 20
25
30
A
D
R
+
V38E 1
V38E 2
C
CD8
D
CD4
0
5
10
15
20
2468
%
 
C
D
8
+
 
H
L
A
Weeks post infection
WT 3
0
5
10
15
20
2468
%
 
C
D
8
+
 
H
L
A
Weeks Post Infection
V38E3
0
5
10
15
20
2468
%
 
C
D
4
+
 
H
L
A
Weeks post infection
WT2
WT 3
0
5
10
15
20
2468
%
C
D
4
+
 
H
L
A
Weeks post infection
V38E 3
C
21 29
P
D
Ͳ
1
V38E WT D
6 7
P
D
Ͳ
1
V38E WT
SSC
SSC
5
10
15
20
25
C
D
8
+
 
P
D
-
1
 
+
WT 1
WT 2
WT 3
5
10
15
20
25
30
C
D
8
+
 
P
D
-
1
 
+ V38E 1
V38E 2
V38E 3
5
10
15
20
25
30
 
C
D
4
+
 
P
D
-
1
 
+ WT 1
WT 2
WT 3
5
10
15
20
25
30
C
D
4
+
 
P
D
-
1
 
+ V38E 1
V38E 2
V38E 3
E
0
5
2468
%
C
Weeks  Post infection
0
5
2468
%
Weeks post infection
0
5
2468
%
Weeks post Infection
0
5
2468
%
C
Weeks post infection
Figure 5 Immune activation is seen in the CD8+ T cells from both WT and V38E infected mice. HLADR expression on CD8 (A) and CD4
(B) cells as well as PD1 expression on CD8 (C) and CD4 cells (D) were determined in PBMC obtained from mice at different time points
postinfection. A representative histogram at 8 weeks (top) and serial cumulative data from 3 mice (bottom) is shown. (E) Expression of immune
activation markers HLADR and PD-1 on splenocytes isolated at 8 weeks postinfection. Each symbol represents an individual mouse.
Garg et al. Virology Journal 2011, 8:34
http://www.virologyj.com/content/8/1/34
Page 8 of 13correlation was not seen in the V38E infected groups
(P > 0.05) (Figure 6B and 6D) where CD8 T cell
immune activation is seen in the absence of significant
CD4 decline. Thus in the BLT mouse model, CD8 T
cell activation is most likely mediated by virus replica-
tion. Nevertheless the utility of immune activation as a
marker for CD4 decline and progression to AIDS under
WT infection is validated here.
CCR5 upregulation in CD8 T cells is similar for WT and
V38E infection
CCR5 expression on both CD8 and CD4 cells has also
been associated with disease progression in HIV. In the
humanized mouse model upregulation of CCR5 on CD8
cells has been reported by others [35,36] although upre-
gulation of CCR5 on CD4 cells is a relatively late event
as shown by Brainard et al. We observed that CCR5 was
upregulated on CD8 but not CD4 cells at the 8 week
end point of our experiment in both PBMCs (Figure
7A) and spleen cells (Figure 7B). Although the CCR5
expression in WT infection was somewhat higher than
V38E mutant the results were not statistically significant
(Figure 7C). CCR5 expression on CD4 cells on the other
hand was relatively low in both infections. These find-
ings suggest that CCR5 upregulation also does not vary
between WT and V38E infections although a difference
at the later stages of the infection beyond 20 weeks can-
not be ruled out.
Discussion
While the selective loss of CD4 cells over a prolonged
period of HIV infection is quiet clear, the mechanism
behind this phenomenon remains elusive. We tested the
hypothesis that gp41-induced cell-to-cell fusion activity
is involved in HIV pathogenesis using an HIV variant
with a point mutation in the gp41 region of Env and the
humanized mouse model. Compared to WT virus, CD4
loss and bystander apoptosis were both compromised in
the V38E mutant. These studies are indicative that the
pathogenesis of HIV maybe partially related to the fuso-
genic potential of the Env glycoprotein. Incidentally, the
V38E mutant is one of the Enfuvirtide resistant muta-
tion associated with immunological benefits in patients
undergoing Enfuvirtide therapy [31,40]. Whether the
lack of bystander apoptosis inducing phenotype in the
humanized mice has a relevance to clinical benefits
remains to be seen.
Among the several hypotheses proposed for CD4 loss,
the role of HIV Env mediated bystander cell death is
now gaining strength [22,41]. This is largely due to the
fact that Env glycoprotein is expressed on the surface of
infected cells, binds to CD4 on bystander cells and can
mediate apoptosis [14]. Furthermore, as the depletion of
cells in HIV infection is largely restricted to CD4+ T
cells and Env binds directly to CD4, a role of Env glyco-
protein in further indicated. Although earlier studies
suggested that soluble gp120 could induce apoptosis,
recent studies point to the importance of membrane
expressed Env glycoprotein in bystander apoptosis [41].
The role of gp41 is further strengthened by recent data
suggesting that HIV-mediated bystander cell death can
be inhibited by gp41 specific fusion inhibitor T20 (Enfu-
virtide) [42]. Recent clinical studies have also demon-
strated that certain resistant mutants arising in patients
undergoing Enfuvirtide therapy are associated with CD4
increase even after virological failure [31,40]. Further-
more, the reduction of fusogenic activity in Enfuvirtide
resistant viruses has been demonstrated by Reeves et al
[43]. While binding of Env to CD4 as well as a corecep-
tor CXCR4/CCR5 are both required for apoptosis induc-
tion in vitro, these interactions alone have been shown
to be insufficient for apoptosis induction [44,45]. Using
coculture experiments with receptor expressing cells, we
and others have recently hypothesized that the fusogenic
activity mediated by gp41 is critical for apoptosis induc-
tion in vitro [28,46-49]. Our in vitro data in this study
using WT or V38E infected Sup-T1 cells confirms this
hypothesis. We find that V38E mutant is incapable of
inducing bystander apoptosis in the presence of signifi-
cant infection and replication in SupT1 cell line. Inter-
estingly bystander apoptosis is seen quiet early in WT
infected cultures, suggesting that in fact, a few infected
P = 0 044 P = 0 084
A B
P 0.044
R2=0.344
P 0.084
R2=0.265
P=0.042
R2=0.345 P=0.108
R2= 0.2369
CD
R 0.2369
Figure 6 CD4 decline correlates with CD8 immune activation in
WT mice but not V38E mutant. Correlation of HLADR or PD-1
expression on CD8 cells with CD4 decline in WT and V38E infected
groups was determined using Pearson’s correlation coefficient.
Correlation between HLADR expression on CD8 cells and CD4
decline for WT (A) and V38E (B) is shown. Similarly the correlation
between PD-1 expression on CD8 cells and CD4 decline in WT (C)
and V38E (D) was also determined.
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fected bystander cells. Given that the point mutation in
gp41 restricts the cell-to-cell fusion capacity of the
V38E mutant, while maintaining the virus-cell fusion
activity and consequently virus replication, we can state
that HIV Env mediated apoptosis is at least in part
dependent on Env fusion function. More importantly we
can also state that bystander apoptosis is most likely
independent of virus replication.
The chronic immune activation and CD4 decline as
well as high levels of virus replication seen in the huma-
nized mice makes it a promising model to study HIV
pathogenesis [35,36]. However the mechanism of CD4
loss in this model remained unclear and there is no evi-
dence that CD4 loss in this model is associated with
apoptosis induction in bystander cells or otherwise. The
differential loss of CD4 cells mediated by WT and V38E
virus in the presence of similar levels of viremia is a
strong indicator of the role of gp41 in CD4 loss. Our
study also addressed the question whether bystander
apoptosis was involved in the differential CD4 loss
between the viruses. Bystander apoptosis was first recog-
nized by Finkel et al in lymph nodes from HIV infected
individuals and SIV infected monkeys [10]. Differential
bystander apoptosis has also been demonstrated in the
nonpathogenic SIVsm infection in Sooty Mangabeys
versus SIVmac infection in Rhesus Macaques [6,50].
However none of the previous studies provided any
mechanistic insights into this phenomenon. The fact
that in our study WT virus infection induces extensive
bystander apoptosis that is strikingly absent in V38E
virus infection is evidence that the fusogenic activity of
the Env glycoprotein may play a key role in bystander
apoptosis and consequently CD4 decline in vivo.
Another major immunopatholgical change in HIV
infection is immune activation [51] that has also been
AB SPLEEN PBMC
23 4 25 5
CD8 CD4 CD8 CD4
WT
24 2 24 4
C
C
R
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Figure 7 CCR5 upregulation is seen on CD8 cells in both WT and V38E mutant infected mice. Mice sacrificed at 8 weeks were assayed for
CCR5 expression in both peripheral blood and spleen. Representative histograms of CCR5 expression in CD8 or CD4 cells in PBMCs (A) or Spleen
(B) is shown for both WT and V38E Mutant. (C) Cumulative data from 3 mice on the expression of CCR5 on CD4 or CD8 cells at 8 weeks post
infection in PBMCs or spleen cells is shown.
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Page 10 of 13reported in the humanized mouse model [35,36,39]. How-
ever the correlation between immune activation and CD4
decline in HIV infection is unclear. Our results show that
the immune activation in this model is largely restricted to
C D 8Tc e l lo v e rt h e8 - w e e kp e r i o do fs t u d ys i m i l a rt o
recent findings by others [35,36]. Interestingly immune acti-
vation between V38E and WT virus infection was similar
even though CD4 decline was limited in V38E infection.
Correlation analysis revealed that while in WT infection
CD8 immune activation correlates with CD4 decline this
was not true for V38E infection. Hence, we were able to
dissociate immune activation from CD4 decline in this
model of HIV infection. Another question is what exactly
mediates immune activation in HIV infection. Compromise
of the intestinal epithelial barrier and consequent LPS leak-
age into circulation has been proposed to mediate immune
activation in HIV infection [51]. A recent study by Hofer et
al further demonstrated that immune activation in the
humanized mouse model is a consequence of failure to
clear LPS due to a macrophage dysfunction induced by
HIV infection [39]. In the same study, experimental induc-
tion of immune activation in the absence of HIV infection
failed to induce a CD4 decline, suggesting that immune
activation may not be the cause of CD4 decline in agree-
ment with our results in this study. It has also been sug-
gested that immune activation in CD8 cells maybe more
closely related to active virus replication since the initiation
of HAART therapy and reduction in viral load abrogates
immune activation in HIV infected individuals [52].
Recently, stimulation of TLR 7/8 by HIV ssRNA has also
been proposed as a mechanism of immune activation
induced by HIV infection [52,53]. Hence it is not surprising
that immune activation was seen with the V38E virus as it
replicated to similar levels as WT virus.
Although there are apparent differences between the
humanized mice and human infections, and though the
findings here cannot be directly extrapolated to HIV
pathogenesis in humans, we can still appreciate the differ-
ential pathogenesis of a point mutant of HIV. While the
use of a laboratory adapted X4 (Lai) isolate is also a limita-
tion of our study the major emphasis of our study is on
using the Lai WT and V38E mutant as a model system to
study the phenomenon of bystander apoptosis. Our study
does provide the first direct evidence of bystander apopto-
sis as the mechanism of CD4 decline in the humanized
mouse model. How relevant are these findings to clinical
isolates and HIV pathogenesis in humans remains to be
determined. Further studies using viruses directly isolated
from patients is likely to address these issues. Furthermore
it is known that certain mutations in gp120 that regulate
CD4 binding also affect Env fusogenicity [9,54] and in
turn could also affect bystander apoptosis in vivo.H e n c e
our study supports the idea that targeting different regions
of the Env glycoprotein to select less fusogenic variants
may have clinical benefits. This study represents a first
step in using the humanized mouse model to study differ-
ential pathogenesis of HIV-1 Env variants and opens the
door to further investigation using this model system.
Additional material
Additional File 1: Figure S1: Reduced CD4 decline in humanized
mice after infection with V38E virus compared to WT. Humanized
mice (6 per group) were infected with either WT or V38E mutant virus.
CD4 levels from individual mice (n = 6) for either WT (A) or V38E (B) over
a period of 8 weeks was determined. (C) Pooled data from each group
shows the striking difference in the CD4 decline between the groups (*
p < 0.01, **p < 0.001).
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